Altimmune Inc. (ALT) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Altimmune Inc. (ALT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

6.22

-0.56 (-8.26%)

At close: Jan 14, 2025, 3:59 PM

6.25

0.40%

After-hours Jan 14, 2025, 07:58 PM EST

undefined% (undefined)

Bid	6.23
Market Cap	442.75M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.57
PE Ratio (ttm)	-3.96
Forward PE	n/a
Analyst	Buy

Ask	6.25
Volume	3,403,422
Avg. Volume (20D)	3,251,354
Open	6.78
Previous Close	6.78
Day's Range	6.19 - 6.82
52-Week Range	5.28 - 14.84
Beta	undefined

About ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinica...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 26, 2017

Employees 59

Stock Exchange NASDAQ

Ticker Symbol ALT

Website https://altimmune.com

Analyst Forecast

According to 8 analyst ratings, the average rating for ALT stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 221.29% from the latest price.

Buy 75.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Altimmune Inc. is scheduled to release its earnings on Mar 26, 2025, before market opens.
Analysts project revenue of $620, reflecting a -98.32% YoY shrinking and earnings per share of -0.34, making a 3.03% increase YoY.

Why Price Moved

2 months ago · Source

+29.12%

Altimmune shares are trading higher after the comp... Unlock content with Pro Subscription

2 months ago · Source

+2.05%

Altimmune shares are trading higher after the company announced the completion of its end of Phase 2 meeting with the FDA for Pemvidutide in obesity treatment. The company and FDA are now aligned on key efficacy and safety measures to be studied in its Phase 3 program.

News

2 weeks ago · seekingalpha.com

Altimmune Could Find A Partner For Its Phase 3 Exercise

ALT's end-of-phase 2 meeting with the FDA provided a clear clinical plan for pemvidutide, but the phase 3 program will require 5,000 patients. ALT's $139M in cash is enough to stay afloat for a while ...

3 weeks ago · fool.com

Why Altimmune Was Such a Robustly Healthy Stock on Thursday

Altimmune (ALT 3.54%) had some encouraging news to share with the world as the trading week drew near a close on Thursday. The biotech announced that it will soon ascend to an important, specialized s...

1 month ago · seekingalpha.com

Altimmune 2025: Redefining Obesity And MASH Treatment

Altimmune is entering both obesity and MASH markets with a powerful GLP-1/Glucagon dual-agonist drug called Pemvidutide, offering fat-specific weight loss and muscle preservation with a strong safety ...

1 month ago · youtube.com

Altimmune CEO on what's next for its experimental obesity drug

Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, potential commercial partnership and more.

1 month ago · zacks.com

Altimmune Stock Up More Than 25% in a Month: Here's Why

ALT's recent progress related to the development of the lead product candidate, pemvidutide, for treating obesity and MASH is aiding the stock.

2 months ago · seekingalpha.com

Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge

Results from the phase 2b IMPACT study, using Pemvidutide for the treatment of patients with MASH, expected Q2 of 2025. The global metabolic dysfunction-associated steatohepatitis market size is expec...

2 months ago · seekingalpha.com

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Altimmune, Inc.'s Pemvidutide shows promise as a dual-action treatment for obesity and MASLD/MASH, targeting weight loss, liver health, and cardiovascular support. Their Phase 2 MOMENTUM trial for obe...

2 months ago · seekingalpha.com

Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript

Altimmune, Inc. (NASDAQ:ALT ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Lee Roth - Burns McClellan, Investor Relations Advisors, Altimmune Vipin Garg - Chief E...

2 months ago · marketbeat.com

How Altimmune Could Grab a Big Chunk of the GLP-1 Market

As pharma giants Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO are raking in the cash from their weight loss and diabetes drugs, many other companies want a piece of the pie. They're developing treat...